ALLIANCE PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.35 GBX | -8.28% |
|
-13.68% | -27.53% |
| 08/05 | European Equities Close Higher in Wednesday Trading; Siemens Energy, Alliance Pharma CEOs to Step Down | MT |
| 08/05 | Alliance Pharma Chief Executive to Leave; New CEO to Start May 13 | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 347.1 | 444.1 | 466.6 | 585.4 | 286.2 | 158.6 | 158.6 | - |
| Enterprise Value (EV) 1 | 432.9 | 503.3 | 576 | 672.4 | 388.2 | 250.8 | 228.8 | 204 |
| P/E ratio | 18.6 x | 17.8 x | 57.6 x | 80.6 x | 312 x | 8.91 x | 8.93 x | 7.3 x |
| Yield | 2.19% | 0.64% | 1.84% | 1.55% | 3.35% | 3.44% | 3.54% | 3.18% |
| Capitalization / Revenue | 2.8 x | 3.27 x | 3.59 x | 3.45 x | 1.66 x | 0.87 x | 0.81 x | 0.76 x |
| EV / Revenue | 3.49 x | 3.71 x | 4.44 x | 3.96 x | 2.26 x | 1.37 x | 1.17 x | 0.98 x |
| EV / EBITDA | 13.4 x | 12.8 x | 14.9 x | 13.8 x | 9.91 x | 5.75 x | 5.3 x | 4.44 x |
| EV / FCF | 26.9 x | 17.3 x | 16.9 x | 20.3 x | 24.6 x | 11 x | 7.86 x | 6.69 x |
| FCF Yield | 3.72% | 5.78% | 5.92% | 4.93% | 4.07% | 9.12% | 12.7% | 14.9% |
| Price to Book | 1.38 x | 1.62 x | 1.66 x | 2.07 x | 0.99 x | 0.53 x | 0.5 x | 0.48 x |
| Nbr of stocks (in thousands) | 5,18,103 | 5,28,077 | 5,32,606 | 5,38,045 | 5,39,995 | 5,40,400 | 5,40,400 | - |
| Reference price 2 | 0.6700 | 0.8410 | 0.8760 | 1.088 | 0.5300 | 0.2935 | 0.2935 | 0.2935 |
| Announcement Date | 26/03/19 | 07/04/20 | 23/03/21 | 22/03/22 | 21/03/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 124 | 135.6 | 129.8 | 169.6 | 172 | 183.1 | 196.2 | 208.6 |
| EBITDA 1 | 32.4 | 39.4 | 38.6 | 48.57 | 39.19 | 43.6 | 43.14 | 45.9 |
| EBIT 1 | 28.94 | 37.45 | 36.83 | 45.64 | 35.67 | 40.39 | 40.01 | 42.55 |
| Operating Margin | 23.34% | 27.61% | 28.37% | 26.9% | 20.74% | 22.06% | 20.4% | 20.39% |
| Earnings before Tax (EBT) 1 | 22.8 | 31.08 | 13.02 | 18.16 | 5.208 | 24.68 | 25.37 | 30.21 |
| Net income 1 | 18.36 | 25.01 | 8.027 | 7.319 | 0.936 | 17.31 | 18.11 | 22.1 |
| Net margin | 14.8% | 18.44% | 6.18% | 4.31% | 0.54% | 9.45% | 9.23% | 10.59% |
| EPS 2 | 0.0360 | 0.0472 | 0.0152 | 0.0135 | 0.001700 | 0.0330 | 0.0329 | 0.0402 |
| Free Cash Flow 1 | 16.1 | 29.1 | 34.1 | 33.13 | 15.8 | 22.88 | 29.12 | 30.47 |
| FCF margin | 12.98% | 21.45% | 26.27% | 19.53% | 9.19% | 12.49% | 14.85% | 14.6% |
| FCF Conversion (EBITDA) | 49.69% | 73.86% | 88.34% | 68.2% | 40.31% | 52.47% | 67.51% | 66.38% |
| FCF Conversion (Net income) | 87.71% | 116.35% | 424.82% | 452.62% | 1,688.03% | 132.16% | 160.8% | 137.86% |
| Dividend per Share 2 | 0.0146 | 0.005360 | 0.0161 | 0.0169 | 0.0178 | 0.0101 | 0.0104 | 0.009320 |
| Announcement Date | 26/03/19 | 07/04/20 | 23/03/21 | 22/03/22 | 21/03/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2020 S1 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 70.3 | - | 78.63 | 88.8 | 78.76 | 90.46 | 82.44 | 100.3 |
| EBITDA 1 | - | - | 22.76 | 25.82 | 21.54 | 17.66 | 17.96 | 26.5 |
| EBIT 1 | - | - | 21.66 | 23.98 | 19.82 | 15.85 | 16.28 | 24.9 |
| Operating Margin | - | - | 27.54% | 27.01% | 25.17% | 17.52% | 19.74% | 24.83% |
| Earnings before Tax (EBT) 1 | - | - | 16.52 | 1.642 | 16.48 | -11.27 | 6.236 | 18.2 |
| Net income 1 | - | - | 8.24 | -0.921 | 13.1 | -12.17 | 5.109 | 13.2 |
| Net margin | - | - | 10.48% | -1.04% | 16.64% | -13.45% | 6.2% | 13.16% |
| EPS | - | - | - | - | 0.0240 | - | - | - |
| Dividend per Share 2 | - | 0.005360 | 0.005630 | 0.0113 | 0.005920 | 0.0118 | - | 0.009000 |
| Announcement Date | 24/09/19 | - | 21/09/21 | 22/03/22 | 20/09/22 | 21/03/23 | 26/09/23 | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 85.8 | 59.2 | 109 | 87 | 102 | 92.2 | 70.2 | 45.4 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.648 x | 1.503 x | 2.835 x | 1.791 x | 2.603 x | 2.115 x | 1.628 x | 0.9886 x |
| Free Cash Flow 1 | 16.1 | 29.1 | 34.1 | 33.1 | 15.8 | 22.9 | 29.1 | 30.5 |
| ROE (net income / shareholders' equity) | 8.06% | 6.61% | 9.78% | 12.1% | 8.1% | 7.12% | 6.95% | 8.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | 2.96% | 3.18% | - |
| Assets 1 | - | - | - | - | - | 583.9 | 570.3 | - |
| Book Value Per Share 2 | 0.4900 | 0.5200 | 0.5300 | 0.5200 | 0.5300 | 0.5600 | 0.5800 | 0.6100 |
| Cash Flow per Share 2 | - | - | - | - | 0.0400 | 0.0500 | 0.0700 | 0.0700 |
| Capex 1 | 2.9 | 4.1 | 4.61 | 1.53 | 0.36 | 1.7 | 1.97 | 2.08 |
| Capex / Sales | 2.34% | 3.02% | 3.55% | 0.9% | 0.21% | 0.93% | 1% | 1% |
| Announcement Date | 26/03/19 | 07/04/20 | 23/03/21 | 22/03/22 | 21/03/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.2935
GBP
Average target price
0.6529
GBP
Spread / Average Target
+122.44%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.53% | 198M | |
| +20.17% | 43.74B | |
| +21.99% | 22.26B | |
| +16.41% | 14.9B | |
| +9.85% | 13.39B | |
| +45.08% | 12.12B | |
| -9.70% | 6.92B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.41% | 5.47B |
- Stock Market
- Equities
- APH Stock
- Financials Alliance Pharma plc